A month ago, Zhejiang Huahai revealed a five-year deal to produce and sell Pfizer’s COVID-19 oral antiviral Paxlovid exclusively in China.
Now, not to be outdone, Merck has agreed to a similar arrangement in China with its COVID-19 antiviral pills, which were co-developed by Ridgeback. The New Jersey pharma giant has granted Sinopharm exclusive import and distribution rights to Lagevrio (molnupiravir).
Both Pfizer and Merck’s COVID pills won authorization in the United States in December of last year. The treatments are for those who are recently infected with COVID and are at risk for developing a severe form of the virus.
As Merck and Pfizer were developing their respective COVID pills, there was much anticipation for their potential to change the landscape of COVID treatment.
Both Pfizer and Merck’s COVID pills won authorization in the United States in December of last year. The treatments are for those who are recently infected with COVID and are at risk for developing a severe form of the virus.
As Merck and Pfizer were developing their respective COVID pills, there was much anticipation for their potential to change the landscape of COVID treatment.
